Teva Pharmaceutical Industries said it would buy Allergan’s generics unit for $40.5 billion in cash and stock in a deal that will vault the Israeli company into the top ranks of global drug makers.
from WSJ.com: US Business http://ift.tt/1JK0kXs
via IFTTT
No comments:
Post a Comment